Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma - Trial NCT06365619
Access comprehensive clinical trial information for NCT06365619 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Utah and is currently Not yet recruiting. The study focuses on Melanoma. Target enrollment is 25 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Utah
Timeline & Enrollment
Phase 2
Aug 01, 2024
Aug 01, 2029
Primary Outcome
Rate of pathologic response rate (pCR, mCR/nCR, or pPR) at the time of surgery.
Summary
The goal of this clinical trial is to study the impact of Neoadjuvant ipilimumab and
 nivolumab for melanoma patients that had recurrence during or after adjuvant anti-PD-1
 therapy.
 
 Participants will receive 2 cycles of treatment prior to their standard of care surgery.
 After surgery participants will receive standard of care adjuvant therapy and be followed for
 response.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06365619
Non-Device Trial